ClinConnect ClinConnect Logo
Search / Trial NCT05090748

Study for the Assessment of the Quality of Echocardiographic Clips.

Launched by ULTRASIGHT · Oct 11, 2021

Trial Information

Current as of July 22, 2025

Completed

Keywords

ClinConnect Summary

This pivotal study is a multi-center, multi-reader multi-case (MRMC) study, designed to assess the quality of the clips obtained by novice users when using the UltraSight AI Guidance software. Prior to the study start, there will be a pre-study training phase for training the novice users.

During the study, eligible subject will undergo the echocardiography examination twice on a single study visit (same day): once by one of the novice users when using the UltraSight AI Guidance software, and once by an expert sonographer without the aid of the software.

Each novice user will perform the ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 18 and older
  • 2. Subjects willing and able to give written informed consent.
  • Exclusion Criteria:
  • 1. Emergency (non-elective) admission within 24 h prior to participating in the study
  • 2. Female subjects who are pregnant (women of childbearing potential will perform a urine pregnancy test)
  • 3. Unable to lie as required in all the classic positions for standard TTE exam: supine on back / left decubitus
  • 4. Subjects who currently participate a clinical trial, involving interventional cardiac devices.
  • 5. Subjects who have prior Echo exam with description of Low/Poor quality exam in the echo report
  • 6. Subjects with BMI above 40
  • 7. Subjects experiencing a known or suspected acute cardiac event
  • 8. Subjects with severe chest wall deformity as per previous medical records and physical examination
  • 9. Subjects who have undergone pneumonectomy
  • 10. Subjects whose anatomy does not lend itself to yield diagnosable standard echocardiography clips (i.e. situs inversus with dextrocardia, single ventricle anatomy due to congenital heart disease, etc.).
  • A woman is of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis.).

About Ultrasight

Ultrasight is a pioneering clinical trial sponsor dedicated to advancing medical imaging technologies and enhancing diagnostic capabilities. With a focus on innovative ultrasound solutions, Ultrasight aims to improve patient outcomes through rigorous research and development, clinical validation, and strategic partnerships. The organization is committed to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and efficacy of its products. By leveraging cutting-edge technology and a multidisciplinary approach, Ultrasight strives to transform the landscape of medical imaging and contribute to the future of healthcare.

Locations

Ramat Gan, , Israel

Chicago, Illinois, United States

Milwaukee, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Roberto Lang, MD

Principal Investigator

U of Chicago

Federico Asch, MD

Principal Investigator

Medstar Health Research Institute

Praveen Mehrotra, MD

Principal Investigator

Thomas Jefferson University

Bijoy Khandheria, MD

Principal Investigator

Aurora Saint Luke Medical Center

Robert Klampfner, MD

Principal Investigator

Sheba Medical Center

Danny Spigelstein, MD

Study Director

UltraSight

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials